<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02744352</url>
  </required_header>
  <id_info>
    <org_study_id>823323</org_study_id>
    <nct_id>NCT02744352</nct_id>
  </id_info>
  <brief_title>Single Shot vs Catheter Infraclavicular Brachial Plexus Block After Distal Radius Fracture Repair</brief_title>
  <official_title>Comparison Between Single Shot Versus Continuous Infraclavicular Brachial Plexus Block for Postoperative Analgesia After Distal Radius Fracture: A Prospective Randomized Open Label Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare infraclavicular brachial plexus shot single shot
      block to continuous catheter nerve block done in adult patients who have under gone surgery
      to repair distal radius fractures. Visual analogue scores, opioid consumption, quality of
      recovery and quality of sleep up to 72 hours post operatively will be used for comparison.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      If the patient is willing to participate and signs the consent, he/she will be randomized to
      one of the two treatment groups:

        1. Single shot block

        2. Continuous catheter

      In the institution investigators usually advocate for regional anesthesia and intravenous
      sedation for the repair of open fracture of the distal radius.

      Patients will be monitored during block performance with standard ASA monitors. All patients
      will receive 2 L of oxygen via a nasal cannula. Sedatives will be titrated to effect.
      Midazolam 1-2 mg, and fentanyl 50-100 mcg will be used for sedation.

      Block time out will be preformed according to standard operating procedure. All blocks will
      be done under ultrasound guidance. Sonosite S nerve machine will be used with a low frequency
      curvilinear (C5) US probe with 2-5 MHZ frequency. Both single shot and continuous ICB will be
      performed according to the SOP in the department. Ultrasound survey of the deltopectoral
      groove below the clavicle will take place. The axillary artery and the three cords
      (posterior, medial and lateral) of the brachial plexus will be identified in short axis view
      deeper to the pectoralis minor muscle.

      For single shot blocks: A 4 inch 21 gauge single shot (B-Braun) needle will be introduced
      in-plane towards the posterior cord of the brachial plexus and 1-2 mL of dextrose 5% (D5%)
      bolus will be used to verify correct placement of the needle in the vicinity of the posterior
      cord and adequate spread pattern to both lateral and medical cord. 20 ml of of Ropivicaine
      0.5% will be injected through the needle with intermittent aspiration after each 5 ml bolus
      injection.

      For the continuous block: A 4 gauge 18 inch tuohy needle ( B -Braun) will be introduced
      towards the posterior cord as above. When the needle tip and the pattern of spread is
      confirmed using D5% solution, a 21 gauge catheter will be introduced 2 cm beyond the needle
      tip under ultrasound visualization. The needle will be withdrawn over the catheter. Injection
      of a total of 20 ml of ropivacaine 0.5% ( in divided 5 ml boluses with intermittent
      aspiration) will take place through the catheter while observing the spread of local
      anesthetic under ultrasound. The catheter hub will be affixed to the upper lateral chest with
      sterile occlusive dressings and an anchoring device.

      Block success will be defined as a change in cutaneous sensation to touch with an alcohol pad
      in the posterior, medial and lateral cord distribution over the forearm and the hand within
      30min after injection. Subjects with successful catheter placement per protocol and nerve
      block onset will be retained in the study. Subjects with a failed catheter insertion or
      misplaced catheter indicated by a lack of sensory changes will have their catheter replaced
      or will be single shot blocked and withdrawn from the study.

      Intraoperative sedation will consist of intermittent boluses of midazolam (1-2 mg), fentanyl
      (50-100 mcg) and propofol infusion, titrates to sedation and patient comfort (25-50
      mcg/kg/min).

      All patients will receive prophylaxis for postoperative nausea and vomiting (PONV) during
      surgery. The protocol for prophylaxis against PONV includes administration of 4 mg of
      dexamethasone after induction of anesthesia and 4 mg of ondansetron 20 minutes before
      recovery from anesthesia. Dexamethasone is withheld if the patient has poorly controlled
      diabetes mellitus (DM). Uncontrolled DM will be defined as random blood glucose above 250
      mg/dl.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    prior to its planned completion as anticipated by the protocol due to lack of resources
  </why_stopped>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Actual">October 5, 2018</completion_date>
  <primary_completion_date type="Actual">October 5, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Scores as Measured by the Visual Analog Scale</measure>
    <time_frame>72 hours</time_frame>
    <description>Pain scores at rest and with movement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants Need for Pain Relief as Measured by Opiate Consumption</measure>
    <time_frame>72 hours</time_frame>
    <description>Amount of opiate consumption</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Recovery Score</measure>
    <time_frame>72 hours</time_frame>
    <description>Score of QoR survey to determine recovery status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Insomnia as Measured by Sleep Questionnaire</measure>
    <time_frame>48 hours</time_frame>
    <description>Quality of sleep first 2 nights post surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Range of Motion as Measured by the Disability Assessment of Shoulder and Hand Questionnaire</measure>
    <time_frame>3 months</time_frame>
    <description>Dash questionnaire to measure range of motion of the wrist and fingers 3 months after surgery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Distal Radius Fracture</condition>
  <condition>Post Operative Pain Control</condition>
  <arm_group>
    <arm_group_label>continuous IBP block</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive 60 hour continuous infraclavicular brachial plexus block (0.2% of ropivacaine at 8 milliliter/hour) with initial four intermittent 5ml bolus (20ml) of 0.5% Ropivicaine given preoperatively to help with operative and postoperative pain</description>
  </arm_group>
  <arm_group>
    <arm_group_label>single shot IBP block</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive single shot infraclavicular brachial plexus block with 20ml bolus of 0.5% ropivicaine given preoperatively to help with operative and postoperative pain</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>20ml bolus of 0.5% ropivicaine</intervention_name>
    <description>Local anesthetic</description>
    <arm_group_label>continuous IBP block</arm_group_label>
    <arm_group_label>single shot IBP block</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.2% of ropivacaine at 8 milliliter/hour</intervention_name>
    <description>Local anesthetic</description>
    <arm_group_label>continuous IBP block</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled for open reduction and internal fixation of a distal radius
             fracture

          -  American Society of Anesthesiologists (ASA) physical status I -III

          -  Mentally competent and able to give consent for enrollment in the study

        Exclusion Criteria:

          -  Patient younger than 18 years old

          -  Allergy to local anesthetics, systemic opioids (fentanyl, morphine, hydromorphone and
             any of the drugs included in the standard of care

          -  Patients opting to go under general anesthesia and those refusing the block

          -  Chronic pain syndromes; Patients will be defined to have chronic pain if they are
             using regular daily doses of systemic narcotics for the past 6 months prior to the
             surgery

          -  BMI of 40 or more
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nabil M Elkassabany</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 23, 2016</study_first_submitted>
  <study_first_submitted_qc>April 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2016</study_first_posted>
  <results_first_submitted>March 6, 2020</results_first_submitted>
  <results_first_submitted_qc>March 24, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 25, 2020</results_first_posted>
  <last_update_submitted>March 24, 2020</last_update_submitted>
  <last_update_submitted_qc>March 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>infraclavicular brachial plexus block</keyword>
  <keyword>quality of recovery score</keyword>
  <keyword>pain score</keyword>
  <keyword>disability assessment of shoulder and hand questionnaire</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Radius Fractures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 29, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/52/NCT02744352/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 24, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/52/NCT02744352/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Continuous IBP Block</title>
          <description>Subjects will receive 60 hour continuous infraclavicular brachial plexus block (0.2% of ropivacaine at 8 milliliter/hour) with initial four intermittent 5ml bolus (20ml) of 0.5% Ropivicaine given preoperatively to help with operative and postoperative pain
20ml bolus of 0.5% ropivicaine: Local anesthetic
0.2% of ropivacaine at 8 milliliter/hour: Local anesthetic</description>
        </group>
        <group group_id="P2">
          <title>Single Shot IBP Block</title>
          <description>Subjects will receive single shot infraclavicular brachial plexus block with 20ml bolus of 0.5% ropivicaine given preoperatively to help with operative and postoperative pain
20ml bolus of 0.5% ropivicaine: Local anesthetic</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Continuous IBP Block</title>
          <description>Subjects will receive 60 hour continuous infraclavicular brachial plexus block (0.2% of ropivacaine at 8 milliliter/hour) with initial four intermittent 5ml bolus (20ml) of 0.5% Ropivicaine given preoperatively to help with operative and postoperative pain
20ml bolus of 0.5% ropivicaine: Local anesthetic
0.2% of ropivacaine at 8 milliliter/hour: Local anesthetic</description>
        </group>
        <group group_id="B2">
          <title>Single Shot IBP Block</title>
          <description>Subjects will receive single shot infraclavicular brachial plexus block with 20ml bolus of 0.5% ropivicaine given preoperatively to help with operative and postoperative pain
20ml bolus of 0.5% ropivicaine: Local anesthetic</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                    <count group_id="B2" value="4"/>
                    <count group_id="B3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                    <count group_id="B2" value="4"/>
                    <count group_id="B3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                    <count group_id="B2" value="4"/>
                    <count group_id="B3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain Scores as Measured by the Visual Analog Scale</title>
        <description>Pain scores at rest and with movement.</description>
        <time_frame>72 hours</time_frame>
        <population>Analysis not done because study terminated prior to treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Continuous IBP Block</title>
            <description>Subjects will receive 60 hour continuous infraclavicular brachial plexus block (0.2% of ropivacaine at 8 milliliter/hour) with initial four intermittent 5ml bolus (20ml) of 0.5% Ropivicaine given preoperatively to help with operative and postoperative pain
20ml bolus of 0.5% ropivicaine: Local anesthetic
0.2% of ropivacaine at 8 milliliter/hour: Local anesthetic</description>
          </group>
          <group group_id="O2">
            <title>Single Shot IBP Block</title>
            <description>Subjects will receive single shot infraclavicular brachial plexus block with 20ml bolus of 0.5% ropivicaine given preoperatively to help with operative and postoperative pain
20ml bolus of 0.5% ropivicaine: Local anesthetic</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Scores as Measured by the Visual Analog Scale</title>
          <description>Pain scores at rest and with movement.</description>
          <population>Analysis not done because study terminated prior to treatment.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participants Need for Pain Relief as Measured by Opiate Consumption</title>
        <description>Amount of opiate consumption</description>
        <time_frame>72 hours</time_frame>
        <population>Analysis not done because study terminated prior to treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Continuous IBP Block</title>
            <description>Subjects will receive 60 hour continuous infraclavicular brachial plexus block (0.2% of ropivacaine at 8 milliliter/hour) with initial four intermittent 5ml bolus (20ml) of 0.5% Ropivicaine given preoperatively to help with operative and postoperative pain
20ml bolus of 0.5% ropivicaine: Local anesthetic
0.2% of ropivacaine at 8 milliliter/hour: Local anesthetic</description>
          </group>
          <group group_id="O2">
            <title>Single Shot IBP Block</title>
            <description>Subjects will receive single shot infraclavicular brachial plexus block with 20ml bolus of 0.5% ropivicaine given preoperatively to help with operative and postoperative pain
20ml bolus of 0.5% ropivicaine: Local anesthetic</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Need for Pain Relief as Measured by Opiate Consumption</title>
          <description>Amount of opiate consumption</description>
          <population>Analysis not done because study terminated prior to treatment.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Recovery Score</title>
        <description>Score of QoR survey to determine recovery status</description>
        <time_frame>72 hours</time_frame>
        <population>Study was terminated before patient analysis and follow ups were completed.</population>
        <group_list>
          <group group_id="O1">
            <title>Continuous IBP Block</title>
            <description>Subjects will receive 60 hour continuous infraclavicular brachial plexus block (0.2% of ropivacaine at 8 milliliter/hour) with initial four intermittent 5ml bolus (20ml) of 0.5% Ropivicaine given preoperatively to help with operative and postoperative pain
20ml bolus of 0.5% ropivicaine: Local anesthetic
0.2% of ropivacaine at 8 milliliter/hour: Local anesthetic</description>
          </group>
          <group group_id="O2">
            <title>Single Shot IBP Block</title>
            <description>Subjects will receive single shot infraclavicular brachial plexus block with 20ml bolus of 0.5% ropivicaine given preoperatively to help with operative and postoperative pain
20ml bolus of 0.5% ropivicaine: Local anesthetic</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Recovery Score</title>
          <description>Score of QoR survey to determine recovery status</description>
          <population>Study was terminated before patient analysis and follow ups were completed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Insomnia as Measured by Sleep Questionnaire</title>
        <description>Quality of sleep first 2 nights post surgery</description>
        <time_frame>48 hours</time_frame>
        <population>Analysis not done because study terminated prior to treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Continuous IBP Block</title>
            <description>Subjects will receive 60 hour continuous infraclavicular brachial plexus block (0.2% of ropivacaine at 8 milliliter/hour) with initial four intermittent 5ml bolus (20ml) of 0.5% Ropivicaine given preoperatively to help with operative and postoperative pain
20ml bolus of 0.5% ropivicaine: Local anesthetic
0.2% of ropivacaine at 8 milliliter/hour: Local anesthetic</description>
          </group>
          <group group_id="O2">
            <title>Single Shot IBP Block</title>
            <description>Subjects will receive single shot infraclavicular brachial plexus block with 20ml bolus of 0.5% ropivicaine given preoperatively to help with operative and postoperative pain
20ml bolus of 0.5% ropivicaine: Local anesthetic</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Insomnia as Measured by Sleep Questionnaire</title>
          <description>Quality of sleep first 2 nights post surgery</description>
          <population>Analysis not done because study terminated prior to treatment.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Range of Motion as Measured by the Disability Assessment of Shoulder and Hand Questionnaire</title>
        <description>Dash questionnaire to measure range of motion of the wrist and fingers 3 months after surgery</description>
        <time_frame>3 months</time_frame>
        <population>Analysis not done because study terminated prior to treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Continuous IBP Block</title>
            <description>Subjects will receive 60 hour continuous infraclavicular brachial plexus block (0.2% of ropivacaine at 8 milliliter/hour) with initial four intermittent 5ml bolus (20ml) of 0.5% Ropivicaine given preoperatively to help with operative and postoperative pain
20ml bolus of 0.5% ropivicaine: Local anesthetic
0.2% of ropivacaine at 8 milliliter/hour: Local anesthetic</description>
          </group>
          <group group_id="O2">
            <title>Single Shot IBP Block</title>
            <description>Subjects will receive single shot infraclavicular brachial plexus block with 20ml bolus of 0.5% ropivicaine given preoperatively to help with operative and postoperative pain
20ml bolus of 0.5% ropivicaine: Local anesthetic</description>
          </group>
        </group_list>
        <measure>
          <title>Range of Motion as Measured by the Disability Assessment of Shoulder and Hand Questionnaire</title>
          <description>Dash questionnaire to measure range of motion of the wrist and fingers 3 months after surgery</description>
          <population>Analysis not done because study terminated prior to treatment.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 Years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Continuous IBP Block</title>
          <description>Subjects will receive 60 hour continuous infraclavicular brachial plexus block (0.2% of ropivacaine at 8 milliliter/hour) with initial four intermittent 5ml bolus (20ml) of 0.5% Ropivicaine given preoperatively to help with operative and postoperative pain
20ml bolus of 0.5% ropivicaine: Local anesthetic
0.2% of ropivacaine at 8 milliliter/hour: Local anesthetic</description>
        </group>
        <group group_id="E2">
          <title>Single Shot IBP Block</title>
          <description>Subjects will receive single shot infraclavicular brachial plexus block with 20ml bolus of 0.5% ropivicaine given preoperatively to help with operative and postoperative pain
20ml bolus of 0.5% ropivicaine: Local anesthetic</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Anmol Madaan, Clinical Research Coordinator</name_or_title>
      <organization>University of Pennsylvania</organization>
      <phone>2156623778</phone>
      <email>Anmol.Madaan@Pennmedicine.Upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

